Abstract: The present invention relates to a method of prognosis and/or diagnosis of a pellicular condition of the scalp, based on the measurement of the quantity of the active form of transglutaminase 3. The present invention also relates to a cosmetic treatment method for the scalp, a method for identifying compounds for reducing and/or eliminating the pellicular condition. Finally, the present invention relates to a kit and the use thereof for identifying a compound for reducing and/or eliminating the pellicular condition.

Abstract: In some embodiments, protein biomarker concentration information for a subject is obtained, and is used to determine one or more skin trends likely to be experienced by the subject. Skincare product recommendations are generated based on the protein biomarker concentration information. Feedback on the recommended skincare products may be received, and may be used to improve future recommendations for skincare products for the subject or for other subjects.

Abstract: Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

Abstract: The present invention relates to a method for diagnosing esthetic degradations of skin, in particular linked to pollution, in a subject, comprising a step (a) of determining, in a skin sample of the subject, the level of at least one marker chosen from the group constituted of (i) bacteria of the species Propionibacterim acnes, bacteria of the family Micrococcaceae, bacteria of the genus Brachybacterium, bacteria of the genus Brevibacterium, bacteria of the order Burkholderiales, bacteria of the genus Parococcus, bacteria of the family Rhodobacteraceae and bacteria of the genus Fusobacterium, and (ii) metabolites of these bacteria chosen from 3-hydroxy-3-methylglutarate, 3-methylglutarate/2-methylglutarate, 4-guanidinobutanoate, 4-imidazoleacetate, 5-oxoproline, aconitrate, adipate, alanine, alpha-cetoglutarate, arabonate/xylonate, azelate, beta-citrylglutamate, choline, cis-urocanate, citraconate/glutaconate, fructose, fumarate, gamma-glutamylalanine, gamma-glutamylglutamine, gamma-glutamylglycine, gamma-glu

Abstract: Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

Abstract: Systems, methods, and devices are provided for generating visualizations of facial aging trends based on protein biomarker concentration information. Protein biomarker concentration information is generated by an immunoassay analyzer device. The protein biomarker concentration information is used to predict one or more facial aging trends, such as shiny skin, rough skin, uneven skin tone, eye wrinkles, photo-aging, loss of elasticity, or dilated pores. A visualization, such as a spider diagram or a face aging simulation, is generated and presented.

Abstract: Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

Abstract: In some embodiments, protein biomarker concentration information for a subject is obtained, and is used to determine one or more skin trends likely to be experienced by the subject. Skincare product recommendations are generated based on the protein biomarker concentration information. Feedback on the recommended skincare products may be received, and may be used to improve future recommendations for skincare products for the subject or for other subjects.

Abstract: Systems, methods, and devices are provided for generating visualizations of facial aging trends based on protein biomarker concentration information. Protein biomarker concentration information is generated by an immunoassay analyzer device. The protein biomarker concentration information is used to predict one or more facial aging trends, such as shiny skin, rough skin, uneven skin tone, eye wrinkles, photo-aging, loss of elasticity, or dilated pores. A visualization, such as a spider diagram or a face aging simulation, is generated and presented.

Abstract: The present invention relates to a method for diagnosing a skin displaying signs of dryness, based on the measurement of the level of expression of the gene encoding LCN1. The present invention also relates to a method for the cosmetic treatment of skin. The present invention also relates to a method for identifying a compound suitable for reducing and/or slowing the progression of the signs of dryness of a skin, as well as a kit.